Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 5:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: FINGER II Clear all
Completed Phase 2 Interventional Results available

A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)

NCT04907539
View directory record Official record
Conditions
Colorectal Cancer
Interventions
RXC004, Nivolumab, Denosumab
Drug · Biological
Lead sponsor
Redx Pharma Ltd
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Santa Rosa, California • Indianapolis, Indiana • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Sep 8, 2026, 5:17 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

SpO2 Validation Study-Philips Optimus

NCT07215429
View directory record Official record
Conditions
Pulse Oximetry, Oxygen Measurements, SpO2
Interventions
No intervention
Device
Lead sponsor
Philips Clinical & Medical Affairs Global
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Louisville, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 8, 2026, 5:17 PM EDT
Completed Not applicable Interventional Results available

FINGER Robot Therapy Study

NCT02048826
View directory record Official record
Conditions
Cerebrovascular Accident
Interventions
FINGER I, FINGER II
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Sep 8, 2026, 5:17 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Robot-assisted Training in Children With CP

NCT06450158
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Robot (Amadeo)-assisted Training
Device
Lead sponsor
Cook Children's Health Care System
Other
Eligibility
6 Years to 18 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2029
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 8, 2026, 5:17 PM EDT
Recruiting Phase 2 Interventional

Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma

NCT05960773
View directory record Official record
Conditions
Mesothelioma, Malignant Mesothelioma (MM), Early-stage Mesothelioma, Subclinical Mesothelioma, BRCA1-Associated Protein-1 (BAP1) Mutations, Early-stage BAP1-associated Malignancies
Interventions
Decitabine/cedazuridine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 8, 2026, 5:17 PM EDT
Terminated Phase 1 Interventional

Conversion of Seddon III Nerve Injury to Seddon I/II Nerve Injury

NCT03236064
View directory record Official record
Conditions
Injury of Other Nerves at Wrist and Hand Level of Unspecified Arm, Initial Encounter
Interventions
Polyethylene Glycols
Drug
Lead sponsor
WellSpan Health
Other
Eligibility
16 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
York, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 8, 2026, 5:17 PM EDT
Completed Not applicable Interventional

Reliability of the Freestyle Libre CGM in the Inpatient Setting During the COVID-19 Surge

NCT04417270
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Freestyle Libre 14 day CGM system, Accuchek Inform II platform
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 99 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2021 · Synced Sep 8, 2026, 5:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Novel Brain Signal Feedback Paradigm to Enhance Motor Learning After Stroke

NCT02856035
View directory record Official record
Conditions
Stroke
Interventions
Neural feedback plus FES and motor training
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years to 88 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Sep 8, 2026, 5:17 PM EDT
Not yet recruiting Phase 2Phase 3 Interventional

Dose Response Study of Transdermal Human Insulin in Patients

NCT05159453
View directory record Official record
Conditions
Glucose, High Blood
Interventions
Human Insulin, Finger-actuated, Metered Pump Sprayer
Biological · Device
Lead sponsor
Transdermal Delivery Solutions Corp
Industry
Eligibility
25 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
1
States / cities
Palm Beach Gardens, Florida
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 8, 2026, 5:17 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II

NCT03041324
View directory record Official record
Conditions
Mucopolysaccharidosis II, MPS II
Interventions
SB-913
Biological
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
5 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
5
States / cities
Oakland, California • Chicago, Illinois • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Sep 8, 2026, 5:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Algometer and Category II Pelvic Blocking and Cranial Protocol

NCT00649753
View directory record Official record
Conditions
Pain, Sacroiliac Joint Dysfunction
Interventions
Category II Pelvic Blocking, Category II Pelvic Blocking and Cranial, Cranial Only
Procedure
Lead sponsor
Logan College of Chiropractic
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Chesterfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 22, 2009 · Synced Sep 8, 2026, 5:17 PM EDT
Terminated No phase listed Observational

Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX

NCT04628871
View directory record Official record
Conditions
Hemophilia B, Mucopolysaccharidosis I, Mucopolysaccharidosis II
Interventions
SB-318, SB-913, SB-FIX
Biological
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
5
States / cities
Oakland, California • Chicago, Illinois • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 8, 2026, 5:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluating the Accuracy of an Integrated Vital Sign Measurement Platform

NCT03589716
View directory record Official record
Conditions
Multimorbidity
Interventions
Vital Moto Mod, Welch Allyn Connex Spot Vital Signs Monitor, Capnostream 20 Portable Bedside Capnograph, Welch Allyn 767 Mobile Aneroid Sphygmomanometerand 3M Littmann Master Classic II Teaching Stethoscope, Scifit 1000R cycle ergometer
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Sep 8, 2026, 5:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Filter Ventilation and Ventilation Information on Product Use Behaviors in Cigarette Smokers

NCT04744285
View directory record Official record
Conditions
Cigarette Smoking-Related Carcinoma
Interventions
Cigarette packaging, Data capture, Questionnaire administration
Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
21 Years to 69 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Dec 25, 2023 · Synced Sep 8, 2026, 5:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Digital Ankle Brachial Index (ABI) as a Screening Tool in Detecting Peripheral Arterial Disease

NCT03161327
View directory record Official record
Conditions
Peripheral Artery Disease, Amputation, Smoking, Diabetes, Hypercholesterolemia, Hypertension
Interventions
ABI using QuantaFlo™
Device
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 90 Years
Enrollment
238 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 10, 2018 · Synced Sep 8, 2026, 5:17 PM EDT
Withdrawn Phase 2 Interventional

Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma

NCT06654050
View directory record Official record
Conditions
Mesothelioma, Malignant Mesothelioma (MM), Early-stage Mesothelioma, Subclinical Mesothelioma, BRCA1-Associated Protein-1 (BAP1) Mutations, Early-stage BAP1-associated Malignancies
Interventions
alrizomadlin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 8, 2026, 5:17 PM EDT
Not listed Phase 2 Interventional

Hyperbaric Hyperoxygenation With Radiotherapy and Temozolomide in Adults With Newly Diagnosed Glioblastoma

NCT00936052
View directory record Official record
Conditions
Glioblastomas, Gliosarcoma
Interventions
Hyperbaric Oxygen Therapy
Other
Lead sponsor
Neurological Surgery, P.C.
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Commack, New York • Great Neck, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2010 · Synced Sep 8, 2026, 5:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Dietary Sodium Intake on Vascular Endothelium

NCT01550315
View directory record Official record
Conditions
Postural Tachycardia Syndrome (POTS)
Interventions
Pulsitile Arterial Tonometry (PAT) Protocol, Calf Blood Flow in Reactive Hyperemia (CBF-RH), Evaluation of Forearm-Mediated Dilation
Procedure · Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Sep 8, 2026, 5:17 PM EDT